For More Information, Contact: Michele Scrofani, Vice President HQ Specialty Pharma, LLC 201.857.8290 Paramus, NJ, April 15, 2014 HQ Specialty Pharma and its collaborating partner, WelGrace Research Group, have received tentative approval on its 505(b)(2) application for Esmolol Hydrochloride Premixed Injection, which references Brevibloc® Injection. The product will be available in two...Read More